Author/Authors :
Zsolt Székelyhidi، نويسنده , , J?nos Pat?، نويسنده , , Frigyes W?czek، نويسنده , , Péter B?nhegyi، نويسنده , , B?lint Hegymegi-Barakonyi، نويسنده , , D?niel Ero?s، نويسنده , , Gy?rgy Mész?ros، نويسنده , , Ferenc Holl?sy، نويسنده , , Doris Hafenbradl، نويسنده , , Sabine Obert، نويسنده , , Bert Klebl، نويسنده , , Gyorgy Keri، نويسنده , , L?szl? O?rfi، نويسنده ,
Abstract :
SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.
